Preliminary Report of RTOG 9508: A Phase III Trial Comparing Whole Brain Irradiation Alone Versus Whole Brain Irradiation Plus Stereotactic Radiosurgery for Patients with Two or Three Unresected Brain Metastases
Joel W. Goldwein, MD
Ultima Vez Modificado: 23 de octubre del 2000
Presenter: P. W. Sperduto Affiliation: Radiation Therapy Oncology Group
Brain metastases develop in approximately 25% of all cancer patients. Management with stereotactic radiotherapy for patients with 3 or less solitary lesions remains an area of controversy. This preliminary analysis is of a group of patients treated with whole brain radiation versus whole brain radiotherapy plus a radiosurgical boost.
Patients with 2 or 3 solitary metastases were evaluated in this analysis
Patients were randomized to either 3750 cGy/15 fractions whole brain RT or 3750 cGy/15 fractions whole brain RT + 1500 cGy to 2400 cGy radiosurgical boost (size dependent)
The groups were well balanced for parameters such as KPS, numbers of lesions, and other factors
Median survival in the 2 arms were 5.8 and 6.7 months, and were not significantly different.
Local control was marginally better in the stereotactic boost arm vs. the whole brain alone arm
There was a 20% improvement in Karnofsky status in the radiosurgery arm versus 0% in the whole brain alone arm, and a similar reduction in steroid dependence among patients receiving boost RT.
There was no grade 4 or 5 toxicity in either arm, and 4% grade III toxicity in the boost arm versus 0% in the no-boost arm
In patients with 2 or 3 brain metastases, stereotactic boost following whole brain RT has no impact on survival, improves local control, and may improve quality of life
Patients with 2 or 3 brain metastases may benefit from such therapy in terms of local control and quality of life
Further study will be required to identify subsets of patients who derive the most benefit from this therapy.
Oct 4, 2013 - For patients with brain metastases, hippocampal avoidance whole brain radiotherapy is associated with less memory decline at four months, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 22 to 25 in Atlanta.